Show simple item record

dc.contributor.authorPark, L.
dc.contributor.authorFurey, M.
dc.contributor.authorNugent, A.C.
dc.date.accessioned2019-06-05T18:28:14Z
dc.date.available2019-06-05T18:28:14Z
dc.date.issued2018
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85057790880&doi=10.1093%2fijnp%2fpyy051&partnerID=40&md5=fe469d9ac02a6b43244f58468f8d8af8
dc.identifier.urihttp://hdl.handle.net/10713/9410
dc.description.abstractBackground: This randomized, placebo-controlled, crossover trial examined the antidepressant efficacy of the muscarinic antagonist scopolamine in major depressive disorder subjects with more severe and refractory forms of major depressive disorder relative to previous reports. Methods: Participants included 23 medication-free major depressive disorder subjects (12 F/11 M, 20-55 years) currently experiencing a major depressive episode. Subjects had scored ?20 on the Montgomery-Asberg Depression Rating Scale. Following a single-blind, placebo lead-in, participants were randomized to receive 2 counterbalanced blocks of 3 i.v. infusions of scopolamine (4 ?g/kg) and placebo in a double-blind manner. The primary and secondary outcomes were the Montgomery- Asberg Depression Rating Scale and the Hamilton Anxiety Rating Scale, respectively. Magnetoencephalography and plasma brain-derived neurotrophic factor concentrations were obtained prior to and after each treatment phase. Results: As assessed by both the Montgomery-Asberg Depression Rating Scale and Hamilton Anxiety Rating Scale, scopolamine had no significant antidepressant or anxiolytic effects relative to placebo. No significant drug vs placebo effects were seen in magnetoencephalography gamma power or brain-derived neurotrophic factor plasma concentrations, and brain-derived neurotrophic factor changes did not correlate with change in Montgomery-Asberg Depression Rating Scale score in response to scopolamine. Conclusions: These results do not support the efficacy of scopolamine for more severe or refractory forms of depression. No pre- to post-infusion changes in plasma brain-derived neurotrophic factor were detected, and magnetoencephalography gamma power changed only in the placebo lead-in, suggesting that these biomarker measures were not affected by scopolamine in this cohort. While difficult to interpret given the lack of antidepressant response, the findings suggest that the neurobiological effects of ketamine and scopolamine are at least partly distinct. Copyright 2018 The Author(s).en_US
dc.description.urihttps://dx.doi.org/10.1093/ijnp/pyy051en_US
dc.language.isoen-USen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofInternational Journal of Neuropsychopharmacology
dc.subjectbiomarkersen_US
dc.subjectketamineen_US
dc.subjectmajor depressive disorderen_US
dc.subjectscopolamineen_US
dc.titleNeurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorderen_US
dc.typeArticleen_US
dc.identifier.doi10.1093/ijnp/pyy051
dc.identifier.pmid30184133


This item appears in the following Collection(s)

Show simple item record